IDEAYA Biosciences Inc
IDYA25.020USD
+0.520+2.12%
Fechamento 07/28, 16:00（ET）Cotações atrasadas em 15 min
2.19BValor de mercado
PerdaP/L TTM
Mais detalhes de IDEAYA Biosciences Inc Empresa
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Informações da empresa
Código da empresaIDYA
Nome da EmpresaIDEAYA Biosciences Inc
Data de listagemMay 23, 2019
Fundado em2015
CEOMr. Yujiro S. Hata
Número de funcionários131
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 23
Endereço7000 Shoreline Ct, Suite 350
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Telefone16504436209
Sitehttps://www.ideayabio.com/
Código da empresaIDYA
Data de listagemMay 23, 2019
Fundado em2015
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
Por EmpresaUSD
Nome
Receita
Proporção
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
United States
7.00M
100.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
Distribuição de ações
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
8.17%
Janus Henderson Investors
7.31%
The Vanguard Group, Inc.
5.80%
Federated Hermes Global Investment Management Corp.
5.44%
Other
58.29%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
8.17%
Janus Henderson Investors
7.31%
The Vanguard Group, Inc.
5.80%
Federated Hermes Global Investment Management Corp.
5.44%
Other
58.29%
Tipos de investidores
Investidores
Proporção
Investment Advisor
45.54%
Investment Advisor/Hedge Fund
33.49%
Hedge Fund
21.64%
Venture Capital
8.56%
Research Firm
4.37%
Individual Investor
0.91%
Pension Fund
0.77%
Sovereign Wealth Fund
0.59%
Bank and Trust
0.34%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
444
101.86M
116.30%
-6.31M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
2023Q2
313
59.35M
103.37%
+5.88M
2023Q1
290
47.36M
97.90%
-6.95M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
13.13M
14.99%
+167.11K
+1.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.15M
8.17%
+286.75K
+4.18%
Mar 31, 2025
Janus Henderson Investors
6.40M
7.31%
+544.14K
+9.29%
Mar 31, 2025
The Vanguard Group, Inc.
5.08M
5.8%
+14.54K
+0.29%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
4.77M
5.44%
-295.60K
-5.84%
Mar 31, 2025
Point72 Asset Management, L.P.
4.41M
5.04%
+4.27M
+3048.93%
Jun 06, 2025
Logos Global Management LP
3.50M
4%
+500.00K
+16.67%
Mar 31, 2025
State Street Global Advisors (US)
3.45M
3.93%
+125.33K
+3.77%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.39M
3.87%
-395.42K
-10.45%
Mar 31, 2025
Deerfield Management Company, L.P.
3.27M
3.73%
+531.55K
+19.43%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
Tema Oncology ETF
1.99%
ALPS Medical Breakthroughs ETF
1.47%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
SPDR S&P Biotech ETF
0.61%
Direxion Daily S&P Biotech Bull 3X Shares
0.35%
ProShares Ultra Nasdaq Biotechnology
0.21%
Invesco Nasdaq Biotechnology ETF
0.19%
iShares Biotechnology ETF
0.17%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.12%
iShares Russell 2000 Growth ETF
0.12%
Ver Mais
Tema Oncology ETF
Proporção1.99%
ALPS Medical Breakthroughs ETF
Proporção1.47%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.88%
SPDR S&P Biotech ETF
Proporção0.61%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.35%
ProShares Ultra Nasdaq Biotechnology
Proporção0.21%
Invesco Nasdaq Biotechnology ETF
Proporção0.19%
iShares Biotechnology ETF
Proporção0.17%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporção0.12%
iShares Russell 2000 Growth ETF
Proporção0.12%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
